Oxford, UK — 11th March, 2010.
The Scripps Research Institute and the FightAIDS@Home project announce new publications and the discovery of two new anti-HIV compounds.
A recent publication in the Journal of Molecular Biology, on which leading InhibOx scientist Dr. Garrett M. Morris is a co-author, describes a dynamic model of HIV integrase inhibition and drug resistance. This work employed the ligand-protein docking program, AutoDock, of which Garrett is a key developer.
Oxford and Cambridge, UK, July 7, 2010. InhibOx Ltd (Oxford, UK) and the Cambridge Crystallographic Data Centre (Cambridge, UK) announce they that have joined forces to create a uniquely powerful drug discovery service offering. Users of the new service will benefit from the shared depth of expertise that includes extensive commercial drug discovery experience and from the leading proprietary technologies developed by the Oxford and Cambridge bodies.